These pages are under development,please bear with us while we finalise the content.
Standardising prostate cancer hormone (GnRH) injections across NCL
Gonadotropin Releasing Hormone (GnRH) analogue injections, also known as Luteinising Hormone Releasing Hormone (or LHRH) injections are indicated for treatment of men with prostate cancer. The service model for ongoing prescribing and administration of GnRH analogues will be changing for some patients with prostate cancer in NCL.
What is changing?
From 1 January 2022, patients who are currently attending a hospital outpatient clinic for their GnRH analogue injections (for prostate cancer) every three or six months will be advised that, unless it is not clinically appropriate, their next injection will be administered at a local GP practice, usually by the practice nurse. This will take place gradually and be phased in over the next six to nine months.
Patients will remain the clinical responsibility of their specialist hospital team, and will be monitored and able to access their specialist nurse or consultant as they do now. The only change is where they receive their GnRH injections.
Why the change?
At the moment around two thirds of patients in NCL are prescribed and administered their GnRH analogue injection in primary care, whereas the remaining third receive the injection in hospital. NCL CCG and the NCL Cancer Alliance have been working to deliver a service model where all patients receive care that is equitable, fairer and provided closer to their home. This model is considered best practice and is standard in many other areas across the UK. The NCL LCS for GnRH analogue for prostate cancer will enable this service model in NCL.